The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 8, Pages 1707-1714
Publisher
Informa UK Limited
Online
2013-11-22
DOI
10.3109/10428194.2013.828351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).
- (2017) J. L. Wolf et al. JOURNAL OF CLINICAL ONCOLOGY
- Autophagy in Multiple Myeloma: What Makes You Stronger Can Also Kill You
- (2013) Richard G. Carroll et al. CANCER CELL
- Control of Autophagic Cell Death by Caspase-10 in Multiple Myeloma
- (2013) Laurence Lamy et al. CANCER CELL
- The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma
- (2012) Grit Hutter et al. ANNALS OF HEMATOLOGY
- Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors
- (2012) Michael R. Mattern et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis
- (2012) M de Martino et al. BRITISH JOURNAL OF CANCER
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma
- (2012) Yadan Wang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
- Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1
- (2011) Rong Zeng et al. ACTA PHARMACOLOGICA SINICA
- Targeting Autophagy Augments In Vitro and In Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy
- (2011) Y. Pan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Inhibition of proteasome deubiquitinating activity as a new cancer therapy
- (2011) Pádraig D'Arcy et al. NATURE MEDICINE
- Dissection of the assembly pathway of the proteasome lid in Saccharomyces cerevisiae
- (2010) Keisuke Fukunaga et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma
- (2010) G. W. Xu et al. BLOOD
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Multiple Assembly Chaperones Govern Biogenesis of the Proteasome Regulatory Particle Base
- (2009) Minoru Funakoshi et al. CELL
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Effect of autophagy on multiple myeloma cell viability
- (2009) B. Hoang et al. MOLECULAR CANCER THERAPEUTICS
- CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells
- (2009) Silvia Masciarelli et al. MOLECULAR IMMUNOLOGY
- Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways
- (2009) Brenda A. Schulman et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Some assembly required: dedicated chaperones in eukaryotic proteasome biogenesis
- (2008) Andrew R. Kusmierczyk et al. BIOLOGICAL CHEMISTRY
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Autophagy-mediated clearance of aggresomes is not a universal phenomenon
- (2008) Esther S.P. Wong et al. HUMAN MOLECULAR GENETICS
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More